VIR Quote, Financials, Valuation and Earnings

Harrow has a net margin of -6742.75% compared to Vir Biotechnology's net margin of -37.17%. Vir Biotechnology's return on equity of -45.02% beat Harrow's return on equity of -35.99%.

Vir Biotechnology has a consensus price target of $17.63, signalling upside risk potential of 225.79%. On the other hand Harrow has an analysts' consensus of $59.03 which suggests that it could grow by 70.84%. Given that Vir Biotechnology has higher upside potential than Harrow, analysts believe Vir Biotechnology is more attractive than Harrow.

Vir Biotechnology has a beta of 1.224, which suggesting that the stock is 22.375% more volatile than S&P 500. In comparison Harrow has a beta of 0.407, suggesting its less volatile than the S&P 500 by 59.3%.

Vir Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harrow offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vir Biotechnology pays -- of its earnings as a dividend. Harrow pays out -- of its earnings as a dividend.

Vir Biotechnology quarterly revenues are $1.8M, which are smaller than Harrow quarterly revenues of $47.8M. Vir Biotechnology's net income of -$121M is lower than Harrow's net income of -$17.8M. Notably, Vir Biotechnology's price-to-earnings ratio is -- while Harrow's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vir Biotechnology is 51.74x versus 5.80x for Harrow. Usually stocks with elevated PS ratios are considered overvalued.

Opus Genetics has a net margin of -6742.75% compared to Vir Biotechnology's net margin of -187.51%. Vir Biotechnology's return on equity of -45.02% beat Opus Genetics's return on equity of -220.73%.

Vir Biotechnology has a consensus price target of $17.63, signalling upside risk potential of 225.79%. On the other hand Opus Genetics has an analysts' consensus of $6.00 which suggests that it could grow by 435.71%. Given that Opus Genetics has higher upside potential than Vir Biotechnology, analysts believe Opus Genetics is more attractive than Vir Biotechnology.

Vir Biotechnology has a beta of 1.224, which suggesting that the stock is 22.375% more volatile than S&P 500. In comparison Opus Genetics has a beta of -0.018, suggesting its less volatile than the S&P 500 by 101.838%.

Vir Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Opus Genetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vir Biotechnology pays -- of its earnings as a dividend. Opus Genetics pays out -- of its earnings as a dividend.

Vir Biotechnology quarterly revenues are $1.8M, which are smaller than Opus Genetics quarterly revenues of $4.4M. Vir Biotechnology's net income of -$121M is lower than Opus Genetics's net income of -$8.2M. Notably, Vir Biotechnology's price-to-earnings ratio is -- while Opus Genetics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vir Biotechnology is 51.74x versus 2.38x for Opus Genetics. Usually stocks with elevated PS ratios are considered overvalued.

Janux Therapeutics has a net margin of -6742.75% compared to Vir Biotechnology's net margin of -6391.57%. Vir Biotechnology's return on equity of -45.02% beat Janux Therapeutics's return on equity of -11.37%.

Vir Biotechnology has a consensus price target of $17.63, signalling upside risk potential of 225.79%. On the other hand Janux Therapeutics has an analysts' consensus of $84.12 which suggests that it could grow by 206.11%. Given that Vir Biotechnology has higher upside potential than Janux Therapeutics, analysts believe Vir Biotechnology is more attractive than Janux Therapeutics.

Vir Biotechnology has a beta of 1.224, which suggesting that the stock is 22.375% more volatile than S&P 500. In comparison Janux Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Vir Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Janux Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vir Biotechnology pays -- of its earnings as a dividend. Janux Therapeutics pays out -- of its earnings as a dividend.

Vir Biotechnology quarterly revenues are $1.8M, which are larger than Janux Therapeutics quarterly revenues of $439K. Vir Biotechnology's net income of -$121M is lower than Janux Therapeutics's net income of -$23.5M. Notably, Vir Biotechnology's price-to-earnings ratio is -- while Janux Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vir Biotechnology is 51.74x versus 117.80x for Janux Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Spero Therapeutics has a net margin of -6742.75% compared to Vir Biotechnology's net margin of -271.3%. Vir Biotechnology's return on equity of -45.02% beat Spero Therapeutics's return on equity of -108.26%.

Vir Biotechnology has a consensus price target of $17.63, signalling upside risk potential of 225.79%. On the other hand Spero Therapeutics has an analysts' consensus of $5.00 which suggests that it could grow by 102.43%. Given that Vir Biotechnology has higher upside potential than Spero Therapeutics, analysts believe Vir Biotechnology is more attractive than Spero Therapeutics.

Vir Biotechnology has a beta of 1.224, which suggesting that the stock is 22.375% more volatile than S&P 500. In comparison Spero Therapeutics has a beta of 1.331, suggesting its more volatile than the S&P 500 by 33.062%.

Vir Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spero Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vir Biotechnology pays -- of its earnings as a dividend. Spero Therapeutics pays out -- of its earnings as a dividend.

Vir Biotechnology quarterly revenues are $1.8M, which are smaller than Spero Therapeutics quarterly revenues of $5.1M. Vir Biotechnology's net income of -$121M is lower than Spero Therapeutics's net income of -$13.9M. Notably, Vir Biotechnology's price-to-earnings ratio is -- while Spero Therapeutics's PE ratio is 10.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vir Biotechnology is 51.74x versus 4.76x for Spero Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.